Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6200996A · kind A · utility
9Cited by
8References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2000 |
| Grant date | Mar 13, 2001 |
| Priority date | — |
| Expiry date | Jan 27, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the formula: ##STR1## are useful in treating disease conditions mediated by TNF-.alpha. such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.